MONOPAR THERAPEUTICS (MNPR) News
Filter MNPR News Items
MNPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNPR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MNPR News From Around the Web
Below are the latest news stories about MONOPAR THERAPEUTICS that investors may wish to consider to help them evaluate MNPR as an investment opportunity.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZNMonopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate. |
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025“Past performance won’t guarantee future returns” is one of the first lessons in investing, a useful reminder that we can never tell what the future has in store. At the same time, a strong track record for a particular company can also suggest that the good times just might keep on rolling. So, what does it mean when a stock gains 1,000% or more in a single year? A jump of that magnitude signifies sustained outperformance – and investors will rightly wish to take a closer look. Wall Street’s an |
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsWILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a priva |
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-LuWILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved |
Monopar to Present at the 36th Annual Piper Sandler Healthcare ConferenceWILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Locati |
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsIn-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results |
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockWILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the |
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockWILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fe |
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common StockWILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no ass |